-

GeneDx to Participate in Upcoming Investor Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET.

Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts

Investor Relations:
investors@GeneDx.com

Media:
press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Summary
GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.
Release Versions

Contacts

Investor Relations:
investors@GeneDx.com

Media:
press@GeneDx.com

More News From GeneDx

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List...

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026....

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance....
Back to Newsroom